Juno is just one part of Celgene's master plan

Seattle biotech Juno Therapeutics' (Nasdaq: JUNO) new partner in the immunotherapy game isn't just interested in treatments for cancer. New Jersey biopharmaceutical company Celgene Corp. (Nasdaq: CELG) on Tuesday announced it will acquire San Diego-based autoimmune disease treatment company Receptos for $7.2 billion, about $232 per share. The deal is expected to close in the third quarter. That pile of cash almost makes Celgene's recent $1 billion deal with Juno—the largest upfront payment for…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news